[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630116":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":30,"centralContacts":30,"locations":30,"responsibleParty":37,"collaborators":30,"id":39,"slug":40,"hasResults":41,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":30,"eligibilityCriteria":45,"healthyVolunteers":41,"sex":46,"minAge":47,"maxAge":48,"enrollmentInfo":49,"targetDuration":30,"studyType":52,"phases":53,"briefSummary":55,"conditions":56,"keywords":30,"overallStatus":58,"whyStopped":30,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":63,"completionDateStruct":65,"leadSponsor":67,"locationsCount":30},{"fullName":5,"class":6},"Hubei Bio-Pharmaceutical Industrial Technological Institute Inc.","INDUSTRY",[8,14,18],{"label":9,"type":10,"description":11,"interventionNames":12},"HW091077 oral dose1","EXPERIMENTAL","HW091077 oral dose1 once a day.",[13],"Drug: HW091077",{"label":15,"type":10,"description":16,"interventionNames":17},"HW091077 dose2","HW091077 oral dose2 once a day.",[13],{"label":19,"type":20,"description":21,"interventionNames":22},"placebo","PLACEBO_COMPARATOR","Matching Placebo for HW091077 oral dose once a day",[23],"Drug: Matching placebo to HW091077",[25,31,33],{"type":26,"name":27,"description":28,"armGroupLabels":29,"otherNames":30},"DRUG","HW091077","HW091077 oral tablet, oral, QD",[15],null,{"type":26,"name":27,"description":28,"armGroupLabels":32,"otherNames":30},[9],{"type":26,"name":34,"description":35,"armGroupLabels":36,"otherNames":30},"Matching placebo to HW091077","Matching placebo to HW091077 oral tablet, oral, QD",[19],{"type":38,"investigatorFullName":30,"investigatorTitle":30,"investigatorAffiliation":30,"oldNameTitle":30,"oldOrganization":30},"SPONSOR","100630116","phase-2-a-phase-2-study-of-hw091077-in-participants-with-refractory-chronic-cough-or-unexplained-chronic-cough-rccucc-100630116",false,"NCT07483489","A Phase 2 Study of HW091077 in Participants With Refractory Chronic Cough Or Unexplained Chronic Cough (RCC\u002FUCC).","A Randomized，Double-Blind, Multicenter，Placebo-Controlled, Parallel-Arm, Phase 2 Study to Evaluate the Efficacy and Safety of HW091077 in Participants With Refractory Chronic Cough or Unexplained Chronic Cough (RCC\u002FUCC).","Inclusion Criteria:\n\n* Aged between 18 and 80 years;\n* Diagnosed with refractory chronic cough or unexplained chronic cough, with a cough lasting for ≥1 year;\n* Chest CT at screening shows no abnormalities that the investigator believes may lead to chronic cough;\n* Cough severity VAS score ≥40 mm ;\n* Female participants of childbearing potential must have a negative pregnancy test and must not be breastfeeding; male and female participants must have no plans for pregnancy during the entire clinical trial and within 6 months after the last dose, and agree to use medically accepted reliable contraceptive methods during the trial and within 6 months after the last dose;\n* Fully understand the study, voluntarily sign the informed consent form, and be able to comply with the study procedures and follow-up requirements.\n\nExclusion Criteria:\n\n* Currently smoking, or having quit smoking within 12 months prior to screening;\n* A smoking history of \\>20 pack-years;\n* Ongoing exposure to inhaled toxic substances within 12 months prior to screening or currently;\n* A history of drug abuse or alcoholism (weekly alcohol consumption of 14 units of alcohol: 1 unit = 285 mL of beer, or 25 mL of spirits, or 100 mL of wine);\n* Diagnosed with chronic obstructive pulmonary disease (COPD), chronic bronchitis, cystic fibrosis, pulmonary sarcoidosis, idiopathic pulmonary fibrosis, bronchial asthma (except for cough variant asthma), or other airway\u002Frespiratory diseases that may affect coughing;\n* Respiratory tract infection or significant changes in lung status within 4 weeks prior to screening;\n* FEV1\u002FFVC)\\\u003C60%;\n* Clinically significant electrocardiogram abnormalities, such as QTc interval ≥450 ms, long QT syndrome, etc.;\n* Use of angiotensin-converting enzyme inhibitors (ACEIs) within 3 months prior to screening;\n* Plans to initiate new treatment for RCC\u002FUCC during the trial period;\n* Taste disturbance within 1 month prior to screening;\n* Use of any P2X3 receptor antagonist within 1 year prior to screening;","ALL","18 Years","80 Years",{"count":50,"type":51},180,"ESTIMATED","INTERVENTIONAL",[54],"PHASE2","This is a randomized, multicenter, double-blind, placebo-controlled, parallel-designed phase 2 clinical trial to evaluate the efficacy, safety and pharmacokinetic (PK) characteristics of HW091077 in Chinese adult subjects with refractory chronic cough or unexplained chronic cough (RCC\u002FUCC).",[57],"Refractory Chronic Cough","NOT_YET_RECRUITING","2026-03-16",{"date":61,"type":62},"2026-03-19","ACTUAL",{"date":64,"type":51},"2026-05-01",{"date":66,"type":51},"2028-08-30",{"name":5,"class":6}]